Open Access
ARTICLE
Uropharmacology for the primary care physician
Paul R. Gittens1, Costas D. Lallas1, Mark L. Pe1, Robert Perkel2, Christine Folia3, Leonard G. Gomella1
1
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
2
Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
3
Department of Pharmacy, Hamilton Health Sciences, Hamilton, Ontario, Canada
Address correspondence to Dr. Leonard G. Gomella,
Department of Urology, Kimmel Cancer Center, Thomas
Jefferson University, 1025 Walnut Street, Suite 1112 College
Building, Philadelphia, PA 19107 USA
Canadian Journal of Urology 2008, 15(Suppl.4), 78-91.
Abstract
Advances in the understanding of the pathophysiology
of a variety of urological disorders have resulted in the
development of novel medications to manage these diseases.
While many disorders such as erectile dysfunction,
overactive bladder, hypogonadism and benign prostatic
hypertrophy have traditionally been managed primarily by
urologists, the use of these newer medications has become
commonplace in the primary care setting. For example,
symptomatic benign prostatic hyperplasia therapy, while
historically treated with primary surgical intervention, is
now commonly initially managed with medical therapy.
Prostate cancer patients are being treated with newer
formulations of long term hormone therapy that range
from monthly to yearly administration. Additionally, the
open dialogue about erectile dysfunction can be directly
traced to the development of oral therapy for this condition.
Testosterone replacement therapy can be administered
using a variety of oral, transdermal and intramuscular
therapies in order to minimize side effects and provide a
more consistent dosing pattern. Finally, overactive bladder,
which is a signifi cant problem socially, has many new
medications available for its treatment. This article will
review some of the newer classes of urological medications,
provide an understanding of basic uropharmacology that
may guide treatment recommendations, and provide insight
into the potential adverse side effects and interactions of
these useful medications.
Keywords
uropharmacology, urological medications
Cite This Article
APA Style
Gittens, P.R., Lallas, C.D., Pe, M.L., Perkel, R., Folia, C. et al. (2008). Uropharmacology for the primary care physician. Canadian Journal of Urology, 15(Suppl.4), 78–91.
Vancouver Style
Gittens PR, Lallas CD, Pe ML, Perkel R, Folia C, Gomella LG. Uropharmacology for the primary care physician. Can J Urology. 2008;15(Suppl.4):78–91.
IEEE Style
P.R. Gittens, C.D. Lallas, M.L. Pe, R. Perkel, C. Folia, and L.G. Gomella, “Uropharmacology for the primary care physician,” Can. J. Urology, vol. 15, no. Suppl.4, pp. 78–91, 2008.
Copyright © 2008 The Canadian Journal of Urology.